Bliss Gvs Pharma Limited (IN:BLISSGVS)
:BLISSGVS
Want to see IN:BLISSGVS full AI Analyst Report?
Total Valuation
Bliss Gvs Pharma Limited has a market cap or net worth of ₹46.52B. The enterprise value is ₹50.10B.
Market Cap₹46.52B
Enterprise Value₹50.10B
Share Statistics
Bliss Gvs Pharma Limited has 105,788,970 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding105,788,970
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Bliss Gvs Pharma Limited’s return on equity (ROE) is 0.11 and return on invested capital (ROIC) is 7.33%.
Return on Equity (ROE)0.11
Return on Assets (ROA)0.09
Return on Invested Capital (ROIC)7.33%
Return on Capital Employed (ROCE)0.10
Revenue Per Employee11.16M
Profits Per Employee2.28M
Employee Count831
Asset Turnover0.62
Inventory Turnover2.82
Valuation Ratios
The current PE Ratio of Bliss Gvs Pharma Limited is 38.1. Bliss Gvs Pharma Limited’s PEG ratio is 0.36.
PE Ratio38.1
PS Ratio2.61
PB Ratio2.03
Price to Fair Value2.03
Price to FCF29.58
Price to Operating Cash Flow66.61
PEG Ratio0.36
Income Statement
In the last 12 months, Bliss Gvs Pharma Limited had revenue of 9.27B and earned 1.29B in profits. Earnings per share was 12.23.
Revenue9.27B
Gross Profit5.02B
Operating Income1.31B
Pretax Income1.90B
Net Income1.29B
EBITDA2.35B
Earnings Per Share (EPS)12.23
Cash Flow
In the last 12 months, operating cash flow was 775.52M and capital expenditures -292.48M, giving a free cash flow of 483.04M billion.
Operating Cash Flow775.52M
Free Cash Flow483.04M
Free Cash Flow per Share4.57
Dividends & Yields
Bliss Gvs Pharma Limited pays an annual dividend of ₹0.5, resulting in a dividend yield of 0.28%
Dividend Per Share₹0.5
Dividend Yield0.28%
Payout Ratio4.81%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.23
52-Week Price Change241.27%
50-Day Moving Average316.68
200-Day Moving Average208.54
Relative Strength Index (RSI)74.64
Average Volume (3m)104.36K
Important Dates
Bliss Gvs Pharma Limited upcoming earnings date is Aug 4, 2026, TBA (Confirmed).
Last Earnings DateMay 12, 2026
Next Earnings DateAug 4, 2026
Ex-Dividend Date―
Financial Position
Bliss Gvs Pharma Limited as a current ratio of 4.02, with Debt / Equity ratio of 1.82%
Current Ratio4.02
Quick Ratio3.38
Debt to Market Cap<0.01
Net Debt to EBITDA-0.06
Interest Coverage Ratio10.87
Taxes
In the past 12 months, Bliss Gvs Pharma Limited has paid 548.62M in taxes.
Income Tax548.62M
Effective Tax Rate0.29
Enterprise Valuation
Bliss Gvs Pharma Limited EV to EBITDA ratio is 10.25, with an EV/FCF ratio of 29.42.
EV to Sales2.60
EV to EBITDA10.25
EV to Free Cash Flow29.42
EV to Operating Cash Flow17.36
Balance Sheet
Bliss Gvs Pharma Limited has ₹2.01B in cash and marketable securities with ₹524.91M in debt, giving a net cash position of ₹1.48B billion.
Cash & Marketable Securities₹2.01B
Total Debt₹524.91M
Net Cash₹1.48B
Net Cash Per Share₹14.00
Tangible Book Value Per Share₹115.91
Margins
Gross margin is 49.66%, with operating margin of 14.08%, and net profit margin of 13.93%.
Gross Margin49.66%
Operating Margin14.08%
Pretax Margin20.45%
Net Profit Margin13.93%
EBITDA Margin25.36%
EBIT Margin21.74%
Analyst Forecast
The average price target for Bliss Gvs Pharma Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast7.19%
EPS Growth Forecast82.31%